S&P 500 Financials Sector SEC Filings — March 17, 2026

17-03-2026

American Rebel Holdings Inc entered into a Securities Purchase Agreement issuing a promissory note to 1800 Diagonal Lending LLC with a principal amount of $124,200 purchased for $108,000 (including $16,200 OID), requiring total repayments of $147,487 over 15 monthly installments from April 15, 2026 to June 15, 2027 at an effective 15% interest rate. The note includes high default interest of 22%, acceleration to 150% of outstanding amounts upon events of default, and conversion rights into common stock (limited to 4.99% beneficial ownership, subject to Nasdaq 19.99% rule without stockholder approval), posing dilution risk. Prepayment is permitted at 95% of principal plus interest within the first 180 days without penalty.

• ·5-day grace period for payments; missed payment triggers Event of Default.
• ·Covenant restricts sale of significant assets without Holder consent to avoid shell company status.
• ·Events of Default include failure to pay (after 5 business days notice), covenant breaches (after 20 days notice), bankruptcy, delisting from Exchanges, non-compliance with Exchange Act reporting.
• ·Conversion rights exercisable only after Event of Default; Notice of Conversion must be before 6pm NY time.
• ·Prepayment requires 3 Trading Days prior notice; no partial prepayments except as specified.

17-03-2026

Cortigent, Inc. (CRGT), a spin-off from Vivani Medical, Inc., is filing Amendment No. 17 to its S-1 for a firm commitment IPO of 1,500,000 shares of common stock at an anticipated $10.00 per share, with an underwriter option for 225,000 additional shares; post-IPO, Vivani will own approximately 77% of voting power, making Cortigent a controlled company. The company develops investigational brain implant devices including the Orion Visual Prosthesis (targeting $4B US TAM for 82,000 profoundly blind Americans) and Stroke Recovery System ($6B annual US TAM amid 610,000 annual strokes), building on the discontinued Argus II system. As an emerging growth company with no established public market and high investment risks, including FDA approval uncertainties for its products, the offering highlights promising markets but pre-commercial status.

• ·Argus II sales discontinued in 2019 to refocus on Orion
• ·Orion completed 6-year Early Feasibility Study in March 2025 with FDA Breakthrough Device designation
• ·Applied for NYSE American listing under symbol CRGT; offering will not proceed without approval
• ·Emerging growth company and smaller reporting company status
• ·Investigational devices (Orion and Stroke Recovery) require FDA approval; no assurance of success

17-03-2026

On March 15, 2026, Sean Smith resigned as Chief Accounting Officer of QXO, Inc., effective immediately, to pursue employment closer to his family, and agreed to serve in an advisory role until June 30, 2026, with continued compensation including prorated salary, bonus, and equity vesting. The departure is not due to any disagreements on accounting principles, financial statements, or internal controls. On March 16, 2026, Robert Loughran was appointed as Interim Chief Accounting Officer, effective immediately, while the company searches for a permanent successor.

• ·No family relationships between Mr. Loughran and any directors or executive officers.
• ·No arrangements or understandings pursuant to which Mr. Loughran was selected as an officer.
• ·No material transactions involving Mr. Loughran subject to Item 404(a) of Regulation S-K.
• ·Mr. Loughran's prior roles: Partner at Elm Street Advisors (since 2023), CFO at Greenidge Generation Holdings (Jan 2022-Oct 2023), CAO at Greenidge (Jun 2021-Jan 2022), VP Corporate Controller at Tronox Holdings PLC (Apr 2018-Jun 2020), various senior roles at Avon including Group VP CAO (Mar 2016-Mar 2019) and VP Corporate Controller (May 2012-Mar 2016).
• ·Mr. Loughran is a Certified Public Accountant with a BS from University of Connecticut.

17-03-2026

Rallybio Corp filed an S-4 registration statement on March 17, 2026, related to a merger with Candid Therapeutics, forming a combined company with increased SEC compliance burdens post-closing, including a Super 8-K filing, 12-month ineligibility for Form S-3, and restrictions on resales for affiliates. Rallybio equityholders will receive CVRs contingent on monetizing legacy assets and cash proceeds from a July 8, 2025, Membership Interest Purchase Agreement with Recursion Pharmaceuticals, which may expire valueless if unsuccessful. The filing outlines risks such as tax uncertainty on CVRs and subordination of CVR payments.

• ·Merger agreement dated as a subsequent event on 2026-03-01.
• ·Membership Interest Purchase Agreement dated July 8, 2025.
• ·Combined company ineligible for Form S-3 for 12 full calendar months post-Closing; must wait 60 days post-Super 8-K for Form S-8.
• ·Combined company 'ineligible issuer' for three years post-Closing, restricting Form S-1 incorporation, free writing prospectuses, and WKSI status.
• ·Rule 144(i)(2) limits resale of restricted/control securities for one year after Form 10 filing.

17-03-2026

Carlisle Companies Incorporated's DEF 14A proxy statement, filed March 17, 2026, provides pay versus performance disclosures via XBRL tags for fiscal years 2021-2025, covering the Principal Executive Officer (PEO) and Non-PEO Named Executive Officers (NEOs), including adjustments for equity awards, pension values, and fair value changes. The filing details the non-employee director compensation program, comprising annual retainers (partly in shares), committee leadership fees, restricted share grants, and a deferred compensation plan, with benchmarking conducted in April 2024 by Willis Towers Watson confirming market competitiveness. It also outlines board communication protocols addressed to Mr. Frias (Lead Independent Director) and a strict director retirement policy requiring resignation at age 72 or after 18 years of service.

• ·Employee directors receive no additional compensation for board service.
• ·Corporate Governance and Nominating Committee reviews director pay at least every two years.
• ·Communications to directors screened to exclude commercial, irrelevant, or improper topics.
• ·Board address: 16430 North Scottsdale Road, Suite 400, Scottsdale, Arizona 85254, Attention: Secretary.

17-03-2026

Urban One, Inc. reported Q4 2025 net revenue of $97.8M, down 16.5% YoY from $117.1M, with operating loss widening to $54.0M from $1.9M, net loss of $54.4M or $(12.24) per share versus $35.7M or $(7.81), and Adjusted EBITDA falling 38.3% to $15.6M from $26.9M amid weak cable TV delivery (-20% QoQ) and soft radio markets. Full-year 2025 revenue declined to $374.4M from $449.7M, though Adjusted EBITDA of $56.7M met guidance; positively, the company completed a debt exchange on Dec 18, 2025, repurchasing $185.0M of 2028 Notes for $111.0M cash plus $1.1M fee, issuing $60.6M 2030 First Lien Notes and $291.0M 2031 Second Lien Notes, and amending its ABL facility to $75.0M plus $25.0M incremental capacity.

• ·Q4 Radio Broadcasting Adjusted EBITDA $8.7M, down from $15.6M YoY; Cable Television $1.8M, down from $14.5M.
• ·FY 2025 Reach Media Adjusted EBITDA $(1.6M), down from $11.6M.
• ·Dec 31, 2025 total assets $593.0M vs $944.8M at Dec 31, 2024; stockholders' equity $24.6M vs $170.9M.
• ·Impairment of goodwill and intangibles $55.3M in Q4 2025.
• ·Nasdaq compliance regained in January 2026 via reverse stock split effective Jan 22, 2026.

17-03-2026

Citi Trends reported strong Q4 FY2025 results with total sales of $230.4M, up 9.1% YoY from $211.2M and comparable store sales growth of 8.9% (two-year stack 15.3%), alongside FY2025 sales of $820.0M, up 8.9% YoY from $753.1M with 9.7% comps growth (two-year 13.1%). Gross margins expanded 20bps to 39.9% in Q4 and 210bps to 39.6% FY, driving net income of $7.4M in Q4 (vs. $14.2M loss) and $5.2M FY (vs. $43.2M loss), with adjusted EBITDA of $11.9M Q4 (vs. $7.1M) and $11.8M FY (vs. -$14.2M, +$26M). However, SG&A expenses increased nominally to $80.0M in Q4 (vs. $77.5M) and $313.2M FY (vs. $300.2M) due to higher sales volume and incentive compensation, though leveraged 160bps and 120bps respectively on a rate basis.

• ·Opened 3 new stores, remodeled 62 locations, and closed 4 stores in FY2025.
• ·No debt and no borrowings under $75M credit facility.
• ·Q1 FY2026 quarter-to-date comparable store sales trending high-single digits.
• ·FY2026 outlook: total sales growth 6-8%, comps 5-7%, gross margin +100bps, adjusted EBITDA $34M-$38M, capex $35M-$40M, open ~25 stores, remodel 50, close 4.
• ·Equity-based compensation FY2025 totaled $5.4M; expected $5.5M-$6.0M in FY2026.

17-03-2026

Marten Transport, Ltd. (MRTN) filed its definitive DEF 14A proxy statement on March 17, 2026, for the 2026 Annual Meeting of Stockholders on May 5, 2026, proposing the election of seven incumbent directors, an advisory vote to approve executive compensation, and ratification of Grant Thornton LLP as independent auditors for 2026. The record date is March 6, 2026, with 81,589,135 shares of common stock outstanding, requiring a quorum of 40,794,568 shares. Voting details specify majority-of-votes-cast for all proposals, with brokers able to vote on auditor ratification but not on director election or say-on-pay.

• ·Annual Meeting location: Roger Marten Community Center, 120 South Franklin Street, Mondovi, Wisconsin at 2:00 p.m. local time.
• ·Proxy materials expected to be mailed on or about March 17, 2026.
• ·All seven director nominees are current board members, each elected at the prior year's annual meeting.
• ·Broker non-votes have no effect on Proposals 1 and 2 but are not expected on Proposal 3 (routine matter).
• ·Ages of nominees as of February 13, 2026; director service start dates range from 1980 (Randolph L. Marten) to 2023 (Patricia L. Jones).

17-03-2026

Victory Capital Holdings, Inc. (VCTR) submitted an improved acquisition proposal for Janus Henderson Group plc (JHG) on March 17, 2026, offering $40 cash per share plus a 0.250x fixed exchange ratio (31% pro forma ownership), valued at >$56.84 per share (based on $67.36 VCTR share price) or >$59.32 (at $77.27 prior price), up from its prior $30 cash + 0.350x proposal rejected on March 11 citing closing risk concerns. The new terms address prior issues with lower client consent threshold (75% vs Trian's 80%), no financing outs, and improved leverage (3.5x ex-synergies / 2.7x with synergies vs Trian's 3.0x). Pro forma combined company projects $807B AUM, $4.5B 2026E revenue, and $2.2B EBITDA at 49.0% margin, with 50%+ accretion potential, though VCTR's share price declined ~13% from $77.27 (2/25/26) to $67.36 (3/16/26).

• ·Special Committee rejected 2/26 proposal on March 11, 2026, as 'not superior' to Trian offer due to closing risk.
• ·Victory 2/26 proposal required 75% client consent; improved matches at 75% vs Trian's 80%.
• ·Victory proposals have 3% termination fee vs Trian's 4%; no Trian voting agreement required.
• ·Trian reverse termination fee: $222.85MM from equity investors.

17-03-2026

Energy Vault reported FY2025 revenue of $203.7 million, up over 340% YoY from $46.2 million, driven by project executions in Australia and U.S., with Q4 revenue surging to $153.3 million from $33.5 million prior year; contract backlog hit a record $1.3 billion, up 300% YoY and 42% sequentially, while cash reached $103.4 million, up 300% YoY. GAAP gross profit rose nearly 8x to $48.0 million with margins expanding to 23.6% from 13.4%, and Q4 Adjusted EBITDA turned positive at $9.8 million versus a $13.4 million loss prior year. However, FY2025 GAAP net loss was $103.6 million, improved from $135.8 million but still substantial, with FY Adjusted EBITDA loss of $21.2 million versus $58.0 million prior year, and 2026 guidance projects ~30% revenue growth to $225-300 million midpoint alongside lower gross margins of 15-25%.

• ·Completed $150M convertible notes in Feb 2026, upsized from $125M, due 2031 with implied conversion price $8.12/share.
• ·Secured 1.5 GWh supply agreement with Peak Energy and exclusive APAC rights.
• ·Asset Vault portfolio includes 150 MW/300 MWh SOSA (Texas), 100 MW/870 MWh EBOR (Australia, option to acquire), targeting $100-150M recurring Adjusted EBITDA by 2029.
• ·Placed 8.5 MW/293 MWh Calistoga and 57 MW/114 MWh Cross Trails in service, expected $10M annualized Adjusted EBITDA.
• ·FY2026 guidance: $75-100M internal Asset Vault project builds at ~15% cash margin (not in GAAP revenue), year-end cash $150-200M.

17-03-2026

Vesicor Therapeutics, Inc., an early-stage biotech and proposed de-SPAC acquisition target for Black Hawk Acquisition Corp (Nasdaq: BKHA, BKHAU, BKHAR), appointed Michael Tolentino, M.D., as CEO effective March 17, 2026, succeeding founder Luo Feng, Ph.D., who transitions to Chief Scientific Officer. Tolentino brings over 20 years of biotech experience, including inventing contributions to Avastin, founding Acuity Pharmaceuticals (merged into OPKO Health), scientific founding Promedior (sold to Roche), and co-founding Aviceda Therapeutics (raised $207.5M Series C) and Avdarna Therapeutics. The company plans to accelerate IND-enabling studies toward a 2027 FDA IND submission, though it notes standard forward-looking risks including lack of current FDA approval and funding needs.

• ·Vesicor has not commenced FDA regulatory approval process for its sole product candidate as of March 17, 2026
• ·Tolentino co-founded Aviceda Therapeutics and served as CSO (2018-2021), CTO/CIO (2018-2025), and board member (2018-2024)
• ·Aikium's Yotta-ML platform targets GLP-1, GIP-1, glucagon agonists, checkpoint inhibitors, and cancer antigens for microvesicle conjugation

17-03-2026

Dragonfly Energy reported preliminary full year 2025 net sales of $58.6 million, up 15.8% YoY driven by 33.8% growth in OEM sales to $36.9 million, though DTC sales declined 8.5% to $20.7 million amid RV market softness. Q4 net sales increased 6.9% to $13.1 million with OEM up 30.1% to $8.1 million, but gross margin contracted to 18.2% from 20.8% and net loss widened to $45.0 million from $9.8 million. The company implemented a strategic cost realignment for $8.9 million in annualized savings and targets positive Adjusted EBITDA at a $70 million annual revenue run rate, while guiding Q1 2026 net sales at $9.5 million and Adjusted EBITDA loss of $4.6 million.

• ·Targets positive Adjusted EBITDA at $70M annual revenue run rate.
• ·Executive and Board cash compensation reduced 20% for remainder of FY2026, replaced with equity incentives.
• ·20% reduction in total payroll expense via workforce reductions and salary adjustments.
• ·Preliminary results subject to audit and potential material adjustments.
• ·Conference call held March 16, 2026 at 4:30 PM ET.

17-03-2026

BioCardia, Inc. announced on March 17, 2026, that the FDA has accepted its pre-submission package for approval of the Helix Transendocardial Delivery Catheter, intended for intramyocardial therapeutic and diagnostic agent delivery. This regulatory milestone advances the product's development pathway. No financial or performance metrics were disclosed.

• ·Filing includes Exhibit 99.1: BioCardia press release dated March 17, 2026
• ·Information furnished under Item 8.01, not deemed 'filed' under Section 18 of the Exchange Act

17-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) issued a press release on March 17, 2026, announcing that its RAD division received an order for 10 RIO Mini units with SARA licenses from a major Midwest construction company. No financial terms or order value were disclosed.

• ·Filing includes Exhibit 99.1: Press release dated March 17, 2026.

17-03-2026

A Paradise Acquisition Corp., a SPAC, is merging with Enhanced, an innovative sports company launching the Enhanced Games that permit FDA-approved performance-enhancing substances under medical supervision to prioritize athlete health, safety, and higher compensation compared to traditional athletics. CEO Max Martin discusses overcoming PED stigma, the Enhanced Games Medical Program run as a clinical study in Abu Dhabi with SSMC Hospital, and benefits for both elite and returning athletes. Accelerate Arbitrage Fund discloses a long position in A Paradise Acquisition shares and rights.

• ·Enhanced Games idea originated roughly 2.5 years ago.
• ·Athletes receive comprehensive baseline assessments and continuous medical screenings as part of the Medical Program.
• ·Focus on two athlete types: prime athletes aiming to break records and older athletes (e.g., mid-30s) seeking personal bests.

17-03-2026

Eureka Acquisition Corp, a SPAC, issued an interest-free $150,000 Extension Promissory Note to Marine Thinking Inc. on March 13, 2026, payable upon consummation of a business combination or the SPAC's term expiry. The note is convertible into private units at $10 per unit if elected prior to closing, with units non-transferable until business combination completion. This supports ongoing merger discussions ahead of a planned Form S-4 registration statement.

• ·Note filed as Exhibit 10.1 in Form 8-K dated March 16, 2026, effective March 17, 2026.
• ·Conversion requires notice at least two business days prior to business combination closing.
• ·Overdue amounts accrue interest at prevailing short-term US Treasury Bill rate.
• ·Annual Report on Form 10-K filed December 15, 2025.

17-03-2026

ProCap Financial, Inc. (BRRWW) filed a DEFA14A Additional Proxy Statement on March 17, 2026. The provided content consists solely of standard forward-looking statement disclaimers, legal notices regarding securities offerings, and contact information for media and investors. No financial metrics, period-over-period comparisons, or material business updates are included.

17-03-2026

Mechanics Bancorp reported net income of $266M in 2025, up 817% YoY from $29M, boosted by a $145M bargain purchase gain from the September 2, 2025 merger with HomeStreet Bank and noninterest income swing to $223M from a $139M loss. Net interest income grew 13% YoY to $586M with NIM expanding 12 bps to 3.43%, while total assets expanded 36% to $22.4B and deposits rose 36% to $19.0B. However, provision for credit losses on loans increased to $20.5M from a $1.6M reversal, nonaccrual loans tripled to $43M (0.30% of total loans), and noninterest expenses rose 36% to $470M driven by $73M acquisition/integration costs.

• ·Common equity Tier 1 capital ratio for Mechanics Bancorp: 14.09% (newly reported post-merger)
• ·Tangible common equity ratio declined to 8.48% from 9.10%
• ·Loans to deposits ratio increased to 74.52% from 69.17%
• ·Full time equivalent employees grew 34% to 1,921

17-03-2026

For the six months ended January 31, 2026, PURE BIOSCIENCE, INC. reported revenue growth of 21.7% YoY to $1.152M, driven by strong performance in PURE Hard Surface (+46.8% to $1.136M for the month), while SILVÉRION revenue declined sharply 91.9% to $14,000. Net loss narrowed 16.0% YoY to $1.249M amid lower G&A expenses, however interest expense rose to $195,000 from $132,000 and dilutive securities outstanding surged 63.3% to 68.6M shares. Convertible notes increased to $5.52M principal plus $625,000 accrued interest.

• ·Fiscal 2026 Notes issued totaling $720K at 6.34%-6.68% interest, maturing Oct-Dec 2028.
• ·G&A expenses decreased 10.2% YoY to $1.498M for six months.
• ·Interest expense increased 47.7% YoY to $195K for six months.

17-03-2026

Pelican Acquisition Corp disclosed under Item 7.01 three promotional discussions on March 13, 14, and 16, 2026, featuring Greenland Energy Company's CEO Robert Price and incoming director Larry G. Swets, Jr., regarding the pending Business Combination with Greenland Exploration Limited, March GL, and PubCo. The filing furnishes transcripts as Exhibits 99.1 and 99.2 and references a Registration Statement on Form S-4 declared effective on February 17, 2026. It emphasizes forward-looking statements with extensive risk factors, including potential delays, redemptions, and failure to complete the merger.

• ·Registration Statement on Form S-4 effective February 17, 2026.
• ·Pelican 10-Q filings: July 31, 2025 (filed September 15, 2025), April 30, 2025 (filed June 27, 2025).
• ·S-1 effective May 22, 2025.

17-03-2026

Cineverse Corp. filed a Form S-3 shelf registration statement on March 16, 2026, to register up to 21,805,701 shares of Class A Common Stock for resale by selling stockholders from time to time on Nasdaq or otherwise. The company will not receive any proceeds from these sales but has agreed to pay certain registration expenses to satisfy registration rights granted to the selling stockholders. The Common Stock (CNVS) had a last reported sale price of $2.60 per share on March 13, 2026.

• ·Registrant classified as non-accelerated filer and smaller reporting company.
• ·Incorporated in Delaware with I.R.S. Employer Identification Number 22-3720962.
• ·Principal executive offices at 224 W. 35th St., Suite 500, #947, New York, New York 10001.
• ·Par value of Common Stock: $0.001 per share.

17-03-2026

Brookfield Infrastructure Partners L.P. reported strong FY2025 financials with revenues up 9.8% YoY to $23.1B, FFO up 6.4% to $2.6B, and net income attributable to the partnership surging 179% to $1.1B, driven by higher other income. However, mark-to-market losses widened to $548M from $26M, and in the Utilities segment, while total Adjusted EBITDA grew 6.1% to $1.3B, Regulated Transmission EBITDA was essentially flat at $552M (up 0.9%) after declining from $631M in 2023. The year featured active portfolio management with acquisitions totaling over $2B (e.g., HomeServe for $1.2B) and divestitures generating ~$1.5B in net proceeds.

• ·Total assets grew 22.5% to $128.2B as of Dec 31, 2025.
• ·Non-recourse borrowings increased to $59.6B from $46.6B.
• ·FFO payout ratio stable at 66% in 2025 vs 67% in 2024.
• ·Agreed sale of Mantiqueira expected to close H1 2026 for $150M.

17-03-2026

Brookfield Infrastructure Corp's annual report for year ended December 31, 2025, reports cash from operating activities declining 8% YoY to $1,608M from $1,743M, while cash used in investing activities improved significantly with a reduced outflow of $612M from $1,110M. Cash used in financing activities worsened to $1,291M outflow from $428M. Non-recourse borrowings totaled $13.5B with projected interest expense of $4.95B, and base management fees grew 6% YoY to $71M.

• ·Exchangeable shares increased slightly to 132,994,956 as of Dec 31, 2025 from 132,051,909 in 2024 (+0.7%).
• ·USD stock highs in Q4 2025 reached $36.41, comparable to $36.42 in Q4 2024, with trading volume increasing to 36.2M units from 21.9M.

17-03-2026

Two Harbors Investment Corp. adjourned its Special Meeting of Stockholders to March 24, 2026, at 11:00 a.m. ET to solicit additional proxies in favor of its proposed acquisition by UWM Holdings Corporation. The Board unanimously recommends voting 'FOR' the Merger Proposal, Non-Binding Compensation Advisory Proposal, and Adjournment Proposal, as detailed in the proxy statement dated February 9, 2026. While the Board views the transaction as in stockholders' best interest, the communication emphasizes significant risks and uncertainties, including potential failure to obtain approvals, integration challenges, and adverse market effects.

• ·Proxy statement/prospectus declared effective by SEC on February 9, 2026; mailing commenced on or about February 12, 2026.
• ·Assistance for voting available via D.F. King toll-free at (888) 887-0082.
• ·Two Harbors 10-K for FY ended December 31, 2025 filed February 17, 2026; UWM 10-K filed February 25, 2026.

17-03-2026

Tenon Medical, Inc. closed a private placement of senior convertible promissory notes with institutional and high net worth investors for gross proceeds of $4.3 million before placement agent fees. The notes have a 20% original issue discount, aggregate principal of $4.3 million, mature on September 11, 2026, and are convertible into common stock after a six-month anniversary at 80% of the VWAP for the prior three trading days. Net proceeds will support commercial expansion, product development, clinical studies, working capital, and general corporate purposes.

• ·Notes not registered under Securities Act of 1933; may not be offered or sold absent registration or exemption
• ·WallachBeth Capital, Inc. acted as placement agent
• ·National launch of Catamaran SI Joint Fusion System in October 2022
• ·Company formed in 2012

17-03-2026

Ethos Technologies Inc. reported revenue of $387.6M for FY 2025, up 52% YoY from $254.9M, driven by strong growth in DTC channel revenue (+40% to $242.5M) and third-party channel revenue (+79% to $145.1M). Gross profit rose 53% to $380.9M with margin expansion to 98% from 97%, and Adjusted EBITDA increased 55% to $89.0M with flat 23% margin; however, net income margin slightly declined to 18% from 19%, sales and marketing expenses surged 54% to $229.3M (59% of revenue), and G&A expenses jumped 77% to $39.6M (10% of revenue).

• ·Contribution profit FY 2025: $162.0M (42% margin) vs FY 2024: $104.6M (41% margin)
• ·Cost of revenue FY 2025: $6.7M vs FY 2024: $6.5M
• ·Depreciation and amortization FY 2025: $5.4M (flat YoY)
• ·Income tax expense FY 2025: $4.6M vs FY 2024: $5.1M

17-03-2026

Hammer Technology Holdings Corp. reported a reduced net loss from continuing operations of $153K for the three months ended January 31, 2026, compared to a $280K loss in the prior year period, driven by lower operating expenses ($139K vs. $348K). Cash and equivalents increased to $28K from $18K at July 31, 2025, supported by $339K in related-party financing, however total assets declined 22% to $182K amid amortization of intangibles, while total liabilities rose 19% to $1.15M and stockholders' deficit worsened to $(968K). For the six months, operating cash burn improved to $328K from $497K, but the company continues to generate no revenue from continuing operations.

• ·Intangible assets declined to $154K from $216K due to amortization.
• ·Selling, general and administrative expenses for six months ended Jan 31, 2026: $242K (down 33% YoY from $363K).
• ·No revenue reported from continuing operations in any period.
• ·Gain on disposal of subsidiaries in prior year discontinued operations: $1.66M for three and six months ended Jan 31, 2025.

17-03-2026

McEwen Inc. reported full-year 2025 revenue of $197.6 million, up 13% YoY from $174.5 million in 2024, driven by a 48% higher average realized price of $3,532 per GEO despite a 22% decline in GEO sales from 100% owned operations to 58,552. Consolidated GEO sales fell 16% to 113,732, including an 9% drop in attributable GEOs from the San José mine to 55,180. Additionally, on February 6, 2026, McEwen Copper secured a loan facility of up to $240 million, with $28.5 million drawn to date at 12% annual interest, to fund the Los Azules Project and other purposes.

• ·Loan proceeds for McEwen Copper to be used for general corporate purposes, working capital, going public transaction costs, and advancing Los Azules Project toward Final Investment Decision.
• ·Company received 203,280 transferable warrants to purchase McEwen Copper shares at $40 per share as part of loan agreement.
• ·Argentina corporate income tax rate changed to progressive 25%-35% for fiscal years starting on/after Jan 1, 2021, with annual inflation adjustments from Jan 2022.

17-03-2026

BW Industrial Holdings Inc., a Delaware-based general building contractor for nonresidential buildings, filed Amendment No. 2 to its S-1 registration statement on March 17, 2026, for an IPO of 2,625,000 shares of common stock on NYSE American under symbol BWGC, with an anticipated price range of $6-$7 per share (midpoint $6.50), targeting gross proceeds of $17.1M. Net proceeds to the company before expenses are estimated at $16.0M after 6% underwriting discounts of $1.0M to lead underwriter Eddid Securities USA Inc., with a 45-day over-allotment option for up to 393,750 additional shares potentially increasing totals to $19.6M gross and $18.4M net. Post-IPO, CEO and Director Yunlong Zhang will retain control with approximately 57.21% voting power, qualifying the company as a 'controlled company' and emerging growth company.

• ·Company address: 2825 Wilcrest Drive, Suite 421, Houston, TX 77042.
• ·I.R.S. Employer Identification No.: 33-4856491.
• ·Standard Industrial Classification Code: 1541 (General Building Contractors - Nonresidential Buildings).
• ·SEC File Number: 333-292504.
• ·Emerging growth company electing reduced reporting requirements under JOBS Act.

17-03-2026

Xerox Holdings Corp reported total revenue of $7.0B for the year ended December 31, 2025, up 12.9% YoY from $6.2B in 2024, driven by IT Solutions revenue surging 112.6% to $761M and post-sale revenue growing 14.3% to $5.5B. However, Print and Other segment profit declined 29.5% to $279M from $396M, total segment profit fell 18.9% to $321M, adjusted operating profit dropped 17.9% to $248M, and total gross margin compressed 4.4 percentage points to 27.1%. Pre-tax loss narrowed to $488M from $1.2B but remained negative amid higher expenses.

• ·Equipment gross margin declined to 21.4% in 2025 from 30.2% in 2024 (-8.8 pts)
• ·Post sale gross margin declined to 28.6% in 2025 from 31.9% in 2024 (-3.3 pts)
• ·SAG as % of revenue improved slightly to 23.6% in 2025 from 24.7% in 2024 (+1.1 pts)
• ·Non-financing interest expense rose to $248M in 2025 from $119M in 2024
• ·Other expenses, net increased to $360M in 2025 from $158M in 2024

17-03-2026

On March 13, 2026, First Industrial Realty Trust, Inc.'s Board of Directors increased its size from six to seven members and elected Frank E. Schmitz as a new director effective June 1, 2026, until the 2027 annual meeting. The Board also approved a new stock repurchase program authorizing up to $250M of common stock purchases, with no specified expiration date and flexibility in execution methods compliant with federal securities laws. A press release was issued on March 16, 2026, regarding these developments amid ongoing proxy solicitation for the 2026 Annual Meeting.

• ·No arrangement or understanding pursuant to which Mr. Schmitz was elected; no related party transactions under Item 404(a) of Regulation S-K.
• ·Repurchase Program may be modified, suspended, or terminated at Board's discretion; open market repurchases to comply with Rule 10b-18.
• ·Preliminary proxy statement filed February 27, 2026, for 2026 Annual Meeting with ongoing solicitation using WHITE proxy card.

17-03-2026

M3-Brigade Acquisition VI Corp., a SPAC formed on June 5, 2025, reported net income of $4.15M for the period ended December 31, 2025, driven by $4.61M in interest income on Investments held in Trust Account totaling $349.6M. However, the company recorded an operating loss of $0.43M from general and administrative costs and a shareholders' deficit of $15.56M primarily due to accretion of Class A ordinary shares subject to redemption. Total assets were $350.8M, including $0.88M in cash, with $34.5M Class A shares at $10.13 redemption value and deferred underwriting fees of $16.4M.

• ·Inception date: June 5, 2025
• ·Balance sheet date: December 31, 2025
• ·Filing date: March 17, 2026
• ·Class A redemption value: $10.13 per share
• ·Net income per share: $0.14 (basic and diluted for both Class A and B)
• ·Auditor: Independent Registered Public Accounting Firm (PCAOB ID: 100)

17-03-2026

Clene Inc. entered into a third-year subaward agreement with New York University on March 13, 2026, for up to $8.0 million under the four-year $45.1 million NIH Grant, supporting the Expanded Access Program for CNM-Au8® treatment of amyotrophic lateral sclerosis from September 1, 2025, to August 31, 2026. This follows prior subawards of $7.3 million for Year 1 (September 2023-August 2024) with Columbia University and $8.0 million for Year 2 (September 2024-August 2025). Funds are reimbursable via monthly invoices, with either party able to terminate on 30 days' notice.

• ·Disbursement based on monthly invoices for reimbursement to Clene Nanomedicine, Inc.
• ·Company retains all rights to Background IP developed at private expense; no licenses granted to NYU or U.S. Government.
• ·Either party may terminate with 30 days' written notice.

17-03-2026

NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI), a clinical-stage biopharmaceutical company developing CNS cancer therapies, appointed David Choi as Chief Accounting Officer effective March 13, 2026, to oversee accounting, financial reporting, internal controls, and governance as it advances Phase II trials. Mr. Choi brings over a decade of experience from Blythe Global Advisors, Grant Thornton, and Ernst & Young, including SEC reporting and SOX compliance. The appointment supports the company's growth with its NEO™ platform, including NEO100™ and NEO212™ under FDA Fast-Track status.

• ·Patent protections extending to 2038.
• ·Exclusively licensed worldwide patent portfolio from University of Southern California for NEO100, NEO212, and related products.
• ·Risk factors referenced in 10-Q for three months ended March 31, 2025.

17-03-2026

ProCap Acquisition Corp, a SPAC, reported net income of $5.66M for the period from inception (Jan 2, 2025) through Dec 31, 2025, driven by $6.11M in interest income from its $256.1M Trust Account, offset by a $0.47M operating loss from G&A expenses. The balance sheet shows total assets of $257.3M, with shareholders' deficit of $10.17M due to accretion of redeemable shares. Cash outside Trust stands at $1.07M, with no business combination completed.

• ·Promissory note to related party: $23,345
• ·Net cash used in operating activities: $0.49M
• ·Net cash provided by financing activities: $251.6M

17-03-2026

AlphaTime Acquisition Corp, a blank check company, is seeking shareholder approval at its March 27, 2026 extraordinary general meeting to extend its business combination deadline from April 4, 2026 to December 4, 2026 via eight one-month extensions, each requiring a $15,000 trust deposit. While the latest extension meeting in December 2025 saw minimal redemptions of only 69 shares ($854), prior meetings resulted in heavy redemptions that reduced the trust account from $70.2M post-IPO to $4.8M currently and outstanding shares from over 6.4M to 2.17M. A January 2024 business combination agreement with HCYC Group remains unconsummated with no guarantees of completion.

• ·Extraordinary general meeting scheduled for March 27, 2026 at 9:00 a.m. ET.
• ·Initial IPO effective December 30, 2022; consummated January 4, 2023.
• ·Business combination agreement signed January 5, 2024, but no guarantee of closing.
• ·Transaction costs for IPO totaled $4,892,699.

17-03-2026

Value Line Inc reported net income of $5.9M for the three months ended January 31, 2026, up 14% YoY to $0.63 per share, driven by strong investment gains of $2.2M (up 229% YoY) and EAM Trust revenues of $4.8M, despite an 8% YoY decline in total publishing revenues to $8.3M and a sharp 36% drop in operating income to $1.0M. For the nine months, net income rose 8% YoY to $18.1M, with publishing revenues down 5% to $25.4M but offset by 9% higher EAM Trust contribution and 51% investment gains growth. Total assets grew 4% to $151M, supported by higher cash and equity securities, though fixed income securities fell 44%.

• ·Net cash provided by operating activities for 9M down 6% YoY to $13.8M.
• ·Net cash from investing activities for 9M down 48% YoY to $8.6M.
• ·Dividends paid for 9M $9.2M, up from $8.5M YoY.
• ·Treasury stock purchases: 612,110 shares at cost $16.5M as of Jan 31, 2026 (up from 589K shares $15.6M).

17-03-2026

Bank7 Corp. reported total assets of $1.82B for 2025, up from $1.72B in 2024 and $1.69B in 2023, with average loans growing 6.6% YoY to $1.48B and net interest income increasing 1.9% to $87.9M; however, net interest margin declined to 4.94% from 5.11%, loan yields dropped to 7.92% from 8.56%, loan interest income fell 1.6% to $117.5M, and total noninterest income decreased 24.4% to $8.5M primarily due to lower oil and gas-related income. Noninterest-bearing deposits declined to $318M from $382M YoY and $434M in 2023, while shareholders' equity grew to $233M.

• ·Equity compensation plans approved by shareholders: 317,046 outstanding options at weighted average exercise price of $16.96, with 623,504 securities remaining available.
• ·Short-term investments average yield declined to 4.21% in 2025 from 5.04% in 2024.
• ·Taxable debt securities average balance dropped to $46.6M in 2025 from $90.2M in 2024.

17-03-2026

United Security Bancshares (UBFO) and Community West Bancshares (CWBC) announced on March 16, 2026, the receipt of regulatory approvals from the FDIC, California Department of Financial Protection and Innovation, and a waiver from the Federal Reserve Bank of San Francisco for their proposed merger, including the merger of UBFO's bank subsidiary into CWBC's. Shareholder approval meetings for both companies are scheduled for March 30, 2026, with closing expected in Q2 2026 subject to approvals and customary conditions. The announcement highlights forward-looking risks such as integration challenges, shareholder approval failures, and potential delays or non-completion.

• ·Press release attached as Exhibit 99.1
• ·CWBC filed Form S-4 registration statement including joint proxy statement/prospectus
• ·Refer to 10-K for Dec 31, 2024 (UBFO) and Dec 31, 2025 (CWBC) for risks

17-03-2026

T. Rowe Price Group Inc's DEF 14A proxy statement nominates 13 directors for election at the 2026 annual meeting, resulting in a board of 13 members with 11 independent directors and an average tenure of approximately 7 years. The board added two new independent directors, Mr. Golston and Mr. Verma, in October 2025, amid Mr. Bartlett's impending retirement, for which a mandatory retirement age exception was granted to retain his expertise during the audit partner rotation at KPMG. The filing highlights robust corporate governance practices, including director independence determinations excluding Messrs. Sharps and August, oversight of sustainability and political activities, and a commitment to board diversity and skills in areas like investment management and risk.

• ·Director tenure ranges from six months to 16 years.
• ·Company does not contribute corporate funds to political candidates, parties, PACs, or independent expenditures.
• ·Board granted exception to Mr. Bartlett's mandatory retirement age for continuity during KPMG audit partner rotation.
• ·Fiscal year ended December 31, 2025; 10-K filed February 13, 2026.

17-03-2026

Core Laboratories Inc. filed an 8-K/A on March 17, 2026, amending its February 4, 2026 earnings release for Q4 and FY ended December 31, 2025, to correct an understated income tax expense of $4.2 million, reducing net income by the same amount and diluted EPS by $0.09 per share. The adjustment arises from tax reconciliations, including deferred tax items related to insurance proceeds from an Aberdeen, U.K. facility fire, with additional prior period corrections such as a $5.6 million write-off of unrecoverable tax receivables and a $4.7 million misclassification. No changes to revenue, operating income, income before tax, or cash from operations.

• ·Form 10-K expected to be filed on or around March 17, 2026
• ·Adjustments are non-cash and do not impact net cash provided by operating activities

17-03-2026

On March 16, 2026, Community West Bancshares (CWBC) and United Security Bancshares (USB) announced receipt of regulatory approvals from the FDIC, California Department of Financial Protection and Innovation, and a waiver from the Federal Reserve Bank of San Francisco for their previously announced merger, including the merger of USB's bank subsidiary into CWBC's. Shareholder approval meetings for both companies are scheduled for March 30, 2026, with closing expected in Q2 2026 subject to approvals and customary conditions. While this advances the transaction, risks include potential shareholder rejection, integration delays, and dilution from new share issuance.

• ·Regulatory approvals from FDIC and California DFPI
• ·Waiver from Federal Reserve Bank of San Francisco
• ·Joint proxy statement/prospectus available on SEC website and company IR sites

17-03-2026

Delta Air Lines, Inc. executives are presenting at the J.P. Morgan Industrials Conference on March 17, 2026, at 7:30 a.m. ET. The presentation materials are furnished as Exhibit 99.1 under Item 7.01 and are not deemed 'filed' for liability purposes. The filing is signed by Daniel C. Janki, Executive Vice President & Chief Financial Officer.

• ·Presentation scheduled for 7:30 a.m. ET on March 17, 2026
• ·Information furnished under Item 7.01 is not deemed 'filed' per General Instruction B.2